Literature DB >> 8645771

Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.

S Szymanski1, J Lieberman, S Pollack, J M Kane, A Safferman, R Munne, D Umbricht, M Woerner, S Masiar, M Kronig.   

Abstract

Gender differences in neuroleptic-refractory chronic schizophrenic disorder patients were examined to determine whether a superior or equivalent antipsychotic response in women vs. men existed similar to that of the general schizophrenic population. Sixty-nine DSM-III schizophrenic patients (47 males and 22 females) were treated with clozapine using a standardized medication regime. The gender differences in these neuroleptic-nonresponsive chronic schizophrenic disorder patients differed from those previously observed in the general schizophrenic population in that an equivalent antipsychotic treatment response in females versus males was not found. These treatment-refractory women appear to be a severely ill subgroup of female schizophrenics with distinct onset of illness, course and treatment response characteristics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645771     DOI: 10.1016/0006-3223(95)00138-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Authors:  Jose de Leon; Francisco J Diaz; Richard C Josiassen; George M Simpson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

Review 2.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.

Authors:  R Joober; C Benkelfat; K Brisebois; A Toulouse; G Turecki; S Lal; D Bloom; A Labelle; P Lalonde; D Fortin; M Alda; R Palmour; G A Rouleau
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

Review 4.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

5.  Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Authors:  T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2018-11-27       Impact factor: 4.384

6.  Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.

Authors:  Yi-lang Tang; Peixian Mao; Feng-Min Li; Wenbiao Li; Qi Chen; Feng Jiang; Zhuo-ji Cai; Philip B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

7.  Sex Differences Distinguish Intracortical Glutamate Receptor-Mediated Regulation of Extracellular Dopamine Levels in the Prefrontal Cortex of Adult Rats.

Authors:  M N Locklear; A B Cohen; A Jone; M F Kritzer
Journal:  Cereb Cortex       Date:  2014-09-26       Impact factor: 5.357

Review 8.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Acute N-methyl-D-aspartate receptor hypofunction induced by MK801 evokes sex-specific changes in behaviors observed in open-field testing in adult male and proestrus female rats.

Authors:  I Feinstein; M F Kritzer
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

10.  Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.

Authors:  Susana Ochoa; Judith Usall; Jesús Cobo; Xavier Labad; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.